Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study-Reference-Cited by-同舟云学术

Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study

Published:2022-03-10 Issue:7 Volume:42 Page:1227-1234
ISSN:1437-160X
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Nakayama Yoichi^ORCID,Watanabe Ryu^ORCID,Murakami Kosaku^ORCID,Murata Koichi^ORCID,Tanaka Masao^ORCID,Ito Hiromu^ORCID,Yamamoto Wataru^ORCID,Ebina Kosuke^ORCID,Hata Kenichiro^ORCID,Hiramatsu Yuri^ORCID,Katayama Masaki^ORCID,Son Yonsu^ORCID,Amuro Hideki^ORCID,Akashi Kengo^ORCID,Onishi Akira^ORCID,Hara Ryota^ORCID,Yamamoto Keiichi^ORCID,Ohmura Koichiro^ORCID,Matsuda Shuichi^ORCID,Morinobu Akio^ORCID,Hashimoto Motomu^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s00296-021-05086-w.pdf

Reference34 articles.

1. Bourne T, Fossati G, Nesbitt A (2008) A PEGylated Fab’ fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 22:331–337. https://doi.org/10.2165/00063030-200822050-00005

2. Rivkin A (2009) Certolizumab pegol for the management of Crohn’s disease in adults. Clin Ther 31:1158–1176. https://doi.org/10.1016/j.clinthera.2009.06.015

3. Ingegnoli F, Castelli R, Gualtierotti R (2013) Rheumatoid factors: clinical applications. Dis Markers 35:727–734. https://doi.org/10.1155/2013/726598

4. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2019) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685–699. https://doi.org/10.1136/annrheumdis-2019-216655

5. Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M et al (2019) Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Arthritis Res Ther 21:91. https://doi.org/10.1186/s13075-019-1880-4

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients;Frontiers in Medicine;2024-09-04

2. Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis;Rheumatology;2024-09-02

3. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study;Rheumatology;2024-05-09

4. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study;RMD Open;2024-02

5. High rheumatoid factor does not diminish efficacy of TNF inhibitors in seropositive JIA;2024-01-24